These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 7716447

  • 1. [Cost-benefit analysis of screening for congenital toxoplasmosis].
    Sagmeister M, Gessner U, Kind C, Horisberger B.
    Schweiz Med Wochenschr Suppl; 1995; 65():103S-112S. PubMed ID: 7716447
    [Abstract] [Full Text] [Related]

  • 2. Cost-benefit analysis of a prenatal preventive programme against congenital syphilis.
    Stray-Pedersen B.
    NIPH Ann; 1980 May; 3(1):57-66. PubMed ID: 6779243
    [Abstract] [Full Text] [Related]

  • 3. Economic evaluation of preventive programmes against congenital toxoplasmosis.
    Stray-Pedersen B, Jenum P.
    Scand J Infect Dis Suppl; 1992 May; 84():86-96. PubMed ID: 1290083
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of prevention strategies for congenital toxoplasmosis: a critical review of medico-economic studies].
    Binquet C, Wallon M, Quantin C, Gadreau M, Peyron F.
    Rev Epidemiol Sante Publique; 2002 Oct; 50(5):475-87. PubMed ID: 12471340
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of HIV screening in pregnant women attending antenatal clinics in India.
    Kumar M, Birch S, Maturana A, Gafni A.
    Health Policy; 2006 Jul; 77(2):233-43. PubMed ID: 16126300
    [Abstract] [Full Text] [Related]

  • 6. [Should a preventive congenital toxoplasmosis program be established in Switzerland?].
    Raeber PA.
    Schweiz Med Wochenschr Suppl; 1995 Jul; 65():5S-9S. PubMed ID: 7716453
    [Abstract] [Full Text] [Related]

  • 7. When does mass screening for open neural tube defects in low-risk pregnancies result in cost savings?
    Tosi LL, Detsky AS, Roye DP, Morden ML.
    CMAJ; 1987 Feb 01; 136(3):255-65. PubMed ID: 2433011
    [Abstract] [Full Text] [Related]

  • 8. [Toxoplasmosis in pregnancy: prevention, prenatal diagnosis and treatment].
    Hohlfeld P, Biedermann K, Extermann P, Gyr T.
    Schweiz Med Wochenschr Suppl; 1995 Feb 01; 65():62S-69S. PubMed ID: 7716455
    [Abstract] [Full Text] [Related]

  • 9. [Prevention of congenital toxoplasmosis in Europe].
    Raeber PA, Biedermann K, Just M, Zuber P.
    Schweiz Med Wochenschr Suppl; 1995 Feb 01; 65():96S-102S. PubMed ID: 7716459
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia.
    Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS.
    BJOG; 2007 May 01; 114(5):588-95. PubMed ID: 17355359
    [Abstract] [Full Text] [Related]

  • 11. [Prevention of congenital toxoplasmosis in France. Risk assessment. Results and perspectives of prenatal screening and newborn follow up].
    Ambroise-Thomas P, Schweitzer M, Pinon JM, Thiebaugeorges O.
    Bull Acad Natl Med; 2001 May 01; 185(4):665-83; discussion 684-8. PubMed ID: 11503357
    [Abstract] [Full Text] [Related]

  • 12. Congenital toxoplasmosis in Austria: Prenatal screening for prevention is cost-saving.
    Prusa AR, Kasper DC, Sawers L, Walter E, Hayde M, Stillwaggon E.
    PLoS Negl Trop Dis; 2017 Jul 01; 11(7):e0005648. PubMed ID: 28692640
    [Abstract] [Full Text] [Related]

  • 13. [Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].
    Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Coutinho RA, Jager JC.
    Ned Tijdschr Geneeskd; 1999 Mar 27; 143(13):677-81. PubMed ID: 10321301
    [Abstract] [Full Text] [Related]

  • 14. [Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam].
    Postma MJ, van den Hoek JA, Beck EJ, Heeg B, Jager JC, Coutinho RA.
    Ned Tijdschr Geneeskd; 2000 Apr 15; 144(16):749-54. PubMed ID: 10812443
    [Abstract] [Full Text] [Related]

  • 15. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R, Haas M, Shanahan M.
    Aust N Z J Public Health; 2008 Feb 15; 32(1):43-52. PubMed ID: 18290913
    [Abstract] [Full Text] [Related]

  • 16. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L, Cunningham G.
    Pediatrics; 2006 May 15; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [Abstract] [Full Text] [Related]

  • 17. The cost-effectiveness of prenatal carrier screening for cystic fibrosis.
    Lieu TA, Watson SE, Washington AE.
    Obstet Gynecol; 1994 Dec 15; 84(6):903-12. PubMed ID: 7970468
    [Abstract] [Full Text] [Related]

  • 18. Prenatal screening for cystic fibrosis: an economic analysis.
    Nielsen R, Gyrd-Hansen D.
    Health Econ; 2002 Jun 15; 11(4):285-99. PubMed ID: 12007162
    [Abstract] [Full Text] [Related]

  • 19. [-Toxoplasmosis in pregnancy: arguments in favor of systematic screening in Switzerland-].
    Hohlfeld P.
    Arch Gynecol Obstet; 1995 Jun 15; 256 Suppl():S165-9. PubMed ID: 8619652
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of prenatal population-based fragile X carrier screening.
    Musci TJ, Caughey AB.
    Am J Obstet Gynecol; 2005 Jun 15; 192(6):1905-12; discussion 1912-5. PubMed ID: 15970847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.